Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Exelixis, Inc.

< Previous 1 2 3 4 5 Next >
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.